Micallef Jacob Vincent 4

What Happened

• Jacob Micallef, Chief Scientific Officer of VOLITIONRX (VNRX), was granted 149,000 restricted stock units (RSUs) on February 26, 2026. The award was granted at $0.00 per share (awarded in lieu of cash compensation), so there was no immediate cash transaction.
• The RSUs will be earned in twelve approximately equal monthly installments beginning March 1, 2026; once those installments are earned they remain subject to additional time-based vesting in a single installment on February 26, 2027. Upon vesting and settlement each RSU converts to one share of common stock.

Key Details

• Transaction date: 2026-02-26 (reported on Form 4 filed 2026-02-27).
• Transaction type/code: Award/Grant (A). Grant price: $0.00; total immediate cash value shown: $0.
• Plan: Issued under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation.
• Vesting/earning schedule: Earned in ~12 equal monthly installments starting 3/1/2026; remaining time-based vesting in one installment on 2/26/2027; continued service required.
• Ownership: Shares to be delivered upon vesting will be common stock; the filing notes the shares are held by Borlaug Limited, of which the reporting person is a controlling director and has voting and dispositive control.
• Filing timeliness: Form 4 was filed the day after the grant (filed 2026-02-27 for a 2026-02-26 grant), so appears timely.

Context

• This is an equity award (RSUs) granted instead of cash compensation—not a market purchase or sale—so it reflects compensation practice rather than an immediate buy/sell signal.
• RSUs do not convey shares until they are earned and vested; only after settlement will common stock be delivered and count toward beneficial ownership.